Search results
Results from the WOW.Com Content Network
The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS).
The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. The guidance was provided by pharmacists and doctors whose expertise was in the care of adults.
The two main reference sources providing this information are the British National Formulary (BNF) and the Drug Tariff. There is a section in the Drug Tariff, known unofficially as the " Blacklist ", detailing medicines which are not to be prescribed under the NHS and must be paid for privately by the patient.
British National Formulary and British National Formulary for Children – the UK standard reference in the use and selection of medicines, published in conjunction with the BMJ Group.
British National Formulary (BNF) British National Formulary for Children (BNFC) British Pharmacopoeia Commission (BPC) C. Cochrane Collaboration;
The British Pharmacopoeia is an important statutory component in the control of medicines, which complements and assists the licensing and inspection processes of the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Together with the British National Formulary (BNF), the British Pharmacopoeia defines the UK's pharmaceutical ...
National Institute for Biological Standards and Control – responsible for the standardisation and control of biological medicines; The MHRA has several independent advisory committees which provide the UK Government with information and guidance on the regulation of medicines and medical devices.
Any adverse reaction, however minor, if associated with a new medicine or one that is under continued monitoring (highlighted in the British National Formulary with a black triangle) Any adverse reaction, however minor, if associated with a child (under 18 years of age) or in pregnancy